Sungyoung Kim is the Founder and Chief Executive Officer of Threebrooks Therapeutics, a biotechnology company developing first-in-class small-molecule therapeutics targeting lysosomal ion channels for neurodegenerative diseases. He also serves as the President of the Pohang Bio Industry Association, where he promotes innovation and collaboration within Korea's biotechnology ecosystem.

Dr. Kim has dedicated his research to understanding the role of lysosomal ion channels in maintaining neuronal homeostasis and developing novel therapeutic strategies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Under his leadership, Threebrooks Therapeutics has established an integrated drug discovery platform that combines Cryo-EM structure-guided AI drug discovery with electrophysiology-based functional validation, enabling the rapid identification and optimization of selective ion channel modulators.

The company's lead program, a selective TRPML1 agonist, has demonstrated robust preclinical efficacy across multiple models of neurodegenerative diseases and is currently advancing toward IND-enabling studies. In parallel, Threebrooks has developed the AION™ electrophysiology platform, providing high-quality ion channel screening and characterization services for both academic and industry partners.

Dr. Kim actively collaborates with global pharmaceutical companies, biotechnology firms, and research institutions to accelerate the translation of lysosomal ion channel biology into innovative therapeutics. His current interests include AI-enabled structure-based drug discovery, translational pharmacology, and the development of first-in-class therapies for diseases associated with lysosomal dysfunction.

Presentation Topic: Lysosomal ion channels as therapeutic targets for neurodegeneration diseases

• The emerging role of lysosomal ion channels in neuronal homeostasis and neurodegeneration

• Discovery of selective TRPML1 agonists using Cryo-EM-guided AI drug discovery

• Future perspectives for lysosomal ion channel-targeted therapeutics

• Therapeutic potential of TRPML1 activation for Alzheimer's and Parkinson's diseases

• Electrophysiological validation and translational pharmacology of TRPML1 modulators